
CARBOGEN AMCIS manufacturing license advances services in China
Ella Day | April 23, 2025 | News story | Manufacturing Services, Manufacturing and Production | Carbogen Amcis, China, Corporate, Drug Manufacturing License (DML), Shanghai, manufacturing
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has been successfully granted Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA). This marks a significant step in the company’s expansion into the Chinese pharma market.
The Shanghai site excelled in all regulatory expectations when good manufacturing practices (GMP) were reviewed by the NMPA, meaning that it is thoroughly prepared for early-phase R&D, pilot scale production and commercial GMP manufacture. This reinforces the company’s adherence to regional customers.
Located in the Shanghai Chemical Industry Park (SCIP), the site is expansive, spanning 40,000m². Moreover, it has advanced infrastructure with four separate units, a range of reactor capacities and employs an international team of 140 specialists.
Harry Wong, country manager of CARBOGEN AMCIS Shanghai, commented: “We’re proud that the Shanghai site is equipped to handle highly potent compounds and provide full GMP product release and analytical support.”
CEO, Stephan Fristschi, reflected on the facility’s role in the company’s development: “This achievement strengthens our long-term goal of becoming a trusted partner in the Chinese pharmaceutical market.”
Ella Day
23/4/25
Related Content

Meribel Pharma Solutions launches to take pharma services to new heights
Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …






